Atara Biotherapeutics, Inc. (ATRA)
Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
|
Dr. Anhco Nguyen Ph.D.
|
President, CEO & Director | 1.07M | -- | 1973 |
|
Mr. Kevin G. Sarney CPA
|
Interim Chief Financial Officer | -- | -- | 1965 |
|
Alex Chapman
|
Vice President of Corporate Communications & Investor Relations | -- | -- | -- |
Atara Biotherapeutics, Inc.
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 10
Description
Atara Biotherapeutics, Inc. engages in the development of transformative therapies for patients with cancer and autoimmune disease in the United States and internationally. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) with post-transplant lymphoproliferative disease, as well as other EBV-driven diseases. It also develops ATA3219, an allogeneic CAR T targeting CD19 intended to target B-cell malignancies and autoimmune diseases. The company has research collaboration agreements with Memorial Sloan Kettering Cancer Center, and Council of the Queensland Institute of Medical Research. Atara Biotherapeutics, Inc. was incorporated in 2012 and is headquartered in Thousand Oaks, California.
Corporate Governance
Upcoming Events
November 12, 2026 at 8:00 PM UTC
Atara Biotherapeutics, Inc. Earnings Date
Recent Events
March 23, 2026 at 12:00 AM UTC
CORRESP: A correspondence can be sent as a document with another submission type or can be sent as a separate submission
